George I. Papakostas

Adjunctive pimavanserin can reduce depressive symptoms and improve function in patients with major depression and inadequate antidepressant response. This analysis evaluated the effects of adjunctive pimavanserin on sleep/wakefulness disturbances.

The use of atypical antipsychotics as adjunctive treatment for nonresponsive depression is limited by their side effects. This study explores whether pimavanserin can be both an efficacious and tolerable...

 

 

 

 

 

 

 

 

The FDA has now approved intranasal esketamine as augmention in treatment-resistant depression, and recent studies of its efficacy have been encouraging. This meta-analysis synthesizes the evidence to provide an...

 

This commentary discusses the implications of a recent article by Chen et al that investigated whether a patient's happiness level during ketamine infusion can predict their eventual antidepressant response...

 

Read commentary on inadequate antidepressant response for MDD. Determining where patients are on the response continuum and managing inadequate response.

 

 

Ketamine infusion can produce rapid antidepressant effects, but how to maintain these initial treatment gains remains unclear. This article suggests directions for future investigation in light of past attempts...

Patients with MDD may experience cognitive dysfunctions that make recovery difficult or incomplete. Read this new Academic Highlights to learn to understand and identify problems with cognition in depressed...

 

 

Is one drug good enough? Read this review of 215 double-blind, randomized, placebo-controlled trials to discover which monotherapies have overall short-term efficacy in treating MDD and bipolar depression.

 

 

Understand what is Vortioxetine (Brintellix), an antidepressant for major depressive disorder and treatment-resistant depression.

 

The atypical antipsychotic ziprasidone is effective in depressed patients who don' t respond to antidepressants, but is it safe? Learn about the clinical relevance of possible cardiac, metabolic, and...

 

 

 

 

 

 

 

To optimize treatment choices for patients with treatment-resistant depression (TRD), TRD should be defined accurately and unambiguously. This review examines extant descriptions and staging models of TRD and posits...

Cognitive deficits are common in depression, but studies suggest that cognitive dysfunction is difficult to treat with antidepressants. Can adding an atypical antipsychotic medication to antidepressant treatment help lessen...

 

 

 

 

 

Prior meta-analyses have found vortioxetine to be efficacious for depression. Building on those findings, the present meta-analysis examined the effect that placebo response has on drug-placebo effect size in...